NO20023770L - Indol-3-ylderivater - Google Patents

Indol-3-ylderivater

Info

Publication number
NO20023770L
NO20023770L NO20023770A NO20023770A NO20023770L NO 20023770 L NO20023770 L NO 20023770L NO 20023770 A NO20023770 A NO 20023770A NO 20023770 A NO20023770 A NO 20023770A NO 20023770 L NO20023770 L NO 20023770L
Authority
NO
Norway
Prior art keywords
indole
derivatives
Prior art date
Application number
NO20023770A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023770D0 (no
Inventor
Simon Goodman
Rudolf Gottschlich
Matthias Wiesner
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20023770L publication Critical patent/NO20023770L/no
Publication of NO20023770D0 publication Critical patent/NO20023770D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NO20023770A 2000-02-11 2002-08-09 Indol-3-ylderivater NO20023770D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10006139A DE10006139A1 (de) 2000-02-11 2000-02-11 Indol-3-yl-Derivate
PCT/EP2001/000084 WO2001058893A2 (de) 2000-02-11 2001-01-05 Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren

Publications (2)

Publication Number Publication Date
NO20023770L true NO20023770L (no) 2002-08-09
NO20023770D0 NO20023770D0 (no) 2002-08-09

Family

ID=7630611

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023770A NO20023770D0 (no) 2000-02-11 2002-08-09 Indol-3-ylderivater

Country Status (27)

Country Link
US (1) US6743810B2 (es)
EP (1) EP1254133B9 (es)
JP (1) JP4938194B2 (es)
KR (1) KR20020073585A (es)
CN (1) CN1214026C (es)
AR (1) AR027398A1 (es)
AT (1) ATE293620T1 (es)
AU (2) AU2001231664C1 (es)
BR (1) BR0108154A (es)
CA (1) CA2399813C (es)
CO (1) CO5261548A1 (es)
CZ (1) CZ20022616A3 (es)
DE (2) DE10006139A1 (es)
EC (1) ECSP013923A (es)
ES (1) ES2240400T3 (es)
HU (1) HUP0302671A2 (es)
IL (1) IL151154A0 (es)
MX (1) MXPA02007732A (es)
NO (1) NO20023770D0 (es)
NZ (1) NZ521260A (es)
PE (1) PE20011125A1 (es)
PL (1) PL356427A1 (es)
PT (1) PT1254133E (es)
RU (1) RU2257380C2 (es)
SK (1) SK11152002A3 (es)
WO (1) WO2001058893A2 (es)
ZA (1) ZA200207273B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
US20040138284A1 (en) * 2000-02-11 2004-07-15 Matthias Wiesner Indol-3-yl derivatives
US20020072518A1 (en) * 2000-08-29 2002-06-13 Khanna Ish Kumar Bicyclic alphavbeta3 antagonists
HUP0302718A3 (en) 2000-11-01 2011-03-28 Merck Patent Gmbh Methods and compositions for the treatment of diseases of the eye
GB0028367D0 (en) * 2000-11-21 2001-01-03 Celltech Chiroscience Ltd Chemical compounds
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
PL207175B1 (pl) 2001-08-01 2010-11-30 Merck Patent Gmbh Zastosowanie inhibitorów integryny do wytwarzania kompozycji farmaceutycznych do zapobiegania i/lub terapii chorób oczu
WO2003068253A1 (en) * 2002-02-14 2003-08-21 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases
WO2004020434A1 (ja) * 2002-08-30 2004-03-11 Eisai Co., Ltd. 含窒素芳香環誘導体
US20070208026A1 (en) * 2003-04-07 2007-09-06 Liu Kevin N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
US7592361B2 (en) * 2003-04-28 2009-09-22 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
US7211588B2 (en) 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
DE10337863A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
EP1667668B1 (en) * 2003-10-01 2008-07-02 MERCK PATENT GmbH Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
EP1758856A2 (en) * 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
EP1676834A1 (en) * 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
WO2007024294A2 (en) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
CN102335168B (zh) * 2011-10-25 2014-04-02 合肥博太医药生物技术发展有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗骨质疏松药物中的应用
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
ES2887148T3 (es) 2015-03-25 2021-12-21 Nat Cancer Ct Agente terapéutico contra el cáncer de vías biliares
US12414945B2 (en) 2015-12-17 2025-09-16 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
SG11202007591RA (en) 2018-03-28 2020-09-29 Eisai R&D Man Co Ltd Therapeutic agent for hepatocellular carcinoma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT290523B (de) * 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
GB1148909A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Process for production of novel phenylhydrazone and phenylhydrazine derivatives
US4824850A (en) * 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
US4983615A (en) * 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
IT1244548B (it) * 1991-02-06 1994-07-15 Poli Ind Chimica Spa Derivati della 5-oxo-l-prolina e loro applicazioni farmaceutiche
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
DE69716900T2 (de) * 1996-04-10 2003-07-03 Merck & Co., Inc. Alpha v Beta 3 ANTAGONISTEN
JP2000516936A (ja) * 1996-08-27 2000-12-19 アメリカン・ホーム・プロダクツ・コーポレイション ドパミンｄ２作動薬としておよび５―ｈｔ１ａリガンドとしての４―アミノエトキシインドール
WO1999033798A1 (en) * 1997-12-25 1999-07-08 Yamanouchi Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives
JP5627160B2 (ja) * 1998-02-23 2014-11-19 サウス、アラバマ、メディカル、サイエンス、ファウンデーションＳｏｕｔｈ Ａｌａｂａｍａ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅ Ｆｏｕｎｄａｔｉｏｎ 医薬として用いるインドール−３−プロピオン酸、並びにそれらの塩およびエステル
EE200000488A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
AU3386199A (en) * 1998-04-08 1999-10-25 American Home Products Corporation N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
JP2002510676A (ja) * 1998-04-08 2002-04-09 アメリカン・ホーム・プロダクツ・コーポレイション うつ病治療用のｎ−アリールオキシエチルアミン誘導体
JP4425699B2 (ja) * 2004-05-17 2010-03-03 川崎重工業株式会社 小型滑走艇

Also Published As

Publication number Publication date
CN1398264A (zh) 2003-02-19
ES2240400T3 (es) 2005-10-16
CN1214026C (zh) 2005-08-10
ECSP013923A (es) 2002-09-27
WO2001058893A2 (de) 2001-08-16
NZ521260A (en) 2004-02-27
CO5261548A1 (es) 2003-03-31
PL356427A1 (en) 2004-06-28
HUP0302671A2 (hu) 2003-12-29
AU2001231664C1 (en) 2006-10-05
HK1051863A1 (en) 2003-08-22
AR027398A1 (es) 2003-03-26
US20030045728A1 (en) 2003-03-06
PT1254133E (pt) 2005-09-30
PE20011125A1 (es) 2001-11-07
AU2001231664B2 (en) 2006-02-23
MXPA02007732A (es) 2002-10-11
US6743810B2 (en) 2004-06-01
DE50105955D1 (de) 2005-05-25
KR20020073585A (ko) 2002-09-27
SK11152002A3 (sk) 2003-01-09
CZ20022616A3 (cs) 2002-10-16
BR0108154A (pt) 2003-01-21
ZA200207273B (en) 2003-12-10
ATE293620T1 (de) 2005-05-15
WO2001058893A3 (de) 2002-04-18
CA2399813A1 (en) 2001-08-16
JP2003530319A (ja) 2003-10-14
AU3166401A (en) 2001-08-20
EP1254133B9 (de) 2005-09-07
CA2399813C (en) 2010-03-09
JP4938194B2 (ja) 2012-05-23
RU2257380C2 (ru) 2005-07-27
EP1254133A2 (de) 2002-11-06
IL151154A0 (en) 2003-04-10
RU2002123332A (ru) 2004-01-10
EP1254133B1 (de) 2005-04-20
NO20023770D0 (no) 2002-08-09
DE10006139A1 (de) 2001-08-16

Similar Documents

Publication Publication Date Title
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
NO20024766L (no) Etylendiaminderivater
NO20023770L (no) Indol-3-ylderivater
ATE540013T1 (de) Naphthalinderivate
NO20025590L (no) Fenylglycin-derivater
ATE288437T1 (de) Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
DK1280809T3 (da) Antitumorecteinascidinderivater
ATE298332T1 (de) Decahydro-isochinolinderivate
DE50114491D1 (de) Substituierte C-Cyclohexylmethylamin-Derivative
AR028602A1 (es) Derivados de pirrol
AR028282A1 (es) Derivados de aminofenil pirimidona
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
PT1351959E (pt) Novos derivados de pleuromutilina
ATE403646T1 (de) Aminocyclohexan-derivate
ATE280752T1 (de) Aminomethyl-phenyl-cyclohexanonderivate
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
DE50112454D1 (de) Substituierte 5-amino-1-penten-3-ol-derivate
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
DE60118970D1 (de) Indol- und dihydroindolderivate
NO20024393D0 (no) 2-fenylpyran-4-on-derivater
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate
DK1246793T3 (da) Substituerede aminomethyl-phenyl-cyclohexanderivater
DOP2000000093A (es) Derivados de benzamina
DK1305307T3 (da) Indolderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application